2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of brexucabtagene autoleucel in the NHS in England.

Brexucabtagene autoleucel is not recommended for the treatment of adults 26 years of age and older with relapsed or refractory B-cell acute lymphoblastic leukaemia.

Read NICE appraisal consultation document